Arena Pharmaceuticals, Inc. (ARNA) Posts Q3 Loss of 7c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil prices, producer inflation ease
- Oil falls more than 3% on weaker global demand outlook and US crude buildup
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Jefferies Remains Bullish on Arena Pharma (ARNA) But Tempers Valuation Target on Data from Rival
November 7, 2012 11:26 AM ESTJefferies cut its price target on Arena Pharma (NASDAQ: ARNA) from $20 to $14 following the company's Q3 results and conference call, but maintained a Buy rating on the long-term potential for Belviq.
"ARNA reiterated its plans for Belviq (1Q13 U.S. launch) and... More
